(Q54540098)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

autosomal dominant polycystic kidney disease

19 January 2020

main subject

0 references

autosomal dominant polycystic kidney

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Albert C M Ong

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

23 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

c25-34; discussion c35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

A case for water in the treatment of polycystic kidney disease.

19 January 2020

cites work

1 reference

Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex

21 January 2018

1 reference

Molecular pathogenesis of ADPKD: the polycystin complex gets complex

21 January 2018

1 reference

Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells

21 January 2018

1 reference

Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells

21 January 2018

1 reference

A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes

21 January 2018

1 reference

Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease

21 January 2018

1 reference

Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease

21 January 2018

1 reference

Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype

21 January 2018

1 reference

Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system.

21 January 2018

1 reference

Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption

21 January 2018

1 reference

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

21 January 2018

1 reference

Primary cilia regulate mTORC1 activity and cell size through Lkb1.

21 January 2018

1 reference

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

21 January 2018

1 reference

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

21 January 2018

1 reference

Sirolimus reduces polycystic liver volume in ADPKD patients

21 January 2018

1 reference

Sirolimus therapy to halt the progression of ADPKD.

21 January 2018

1 reference

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

mTOR inhibitors and autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

mTOR inhibitors in polycystic kidney disease.

21 January 2018

1 reference

Randomized intervention studies in human polycystic kidney and liver disease

21 January 2018

1 reference

Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

21 January 2018

1 reference

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Autosomal dominant polycystic kidney disease: the last 3 years

21 January 2018

1 reference

Vasopressin directly regulates cyst growth in polycystic kidney disease

21 January 2018

1 reference

Role of vasopressin antagonists

21 January 2018

1 reference

A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort

21 January 2018

1 reference

The HALT polycystic kidney disease trials: design and implementation

21 January 2018

1 reference

The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease

21 January 2018

1 reference

Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants

21 January 2018

1 reference

Src inhibition ameliorates polycystic kidney disease

21 January 2018

1 reference

Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.

21 January 2018

1 reference

Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy

21 January 2018

1 reference

Triptolide reduces cystogenesis in a model of ADPKD.

21 January 2018

1 reference

Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD

21 January 2018

1 reference

Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models

21 January 2018

1 reference

A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.

21 January 2018

1 reference

Lipids and renal cystic disease

21 January 2018

1 reference

Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells

21 January 2018

1 reference

The therapy of kidney cancer with biomolecular drugs.

21 January 2018

1 reference

PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease

21 January 2018

1 reference

Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant

21 January 2018

1 reference

Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats

21 January 2018

1 reference

PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line

21 January 2018

1 reference

Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity

21 January 2018

1 reference

Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease

21 January 2018

1 reference

In vivo pharmacology and antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents

21 January 2018

1 reference

KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

21 January 2018

1 reference

The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy

21 January 2018

1 reference

Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models

21 January 2018

1 reference

Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts

21 January 2018

1 reference

Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis

21 January 2018

1 reference

Calcimimetic inhibits late-stage cyst growth in ADPKD

21 January 2018

1 reference

Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease

21 January 2018

1 reference

Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000334166

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22205396%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference